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Purpose.  —  The  purpose  of  this  study  was  to  test  fluorine-19  (19F)  cellular  magnetic  resonance
(MRI) as  a  non-invasive  imaging  modality  to  track  therapeutic  cell  migration  as  a  surrogate
marker of  immunotherapeutic  effectiveness.
Materials  and  methods.  —  Human  peripheral  blood  mononuclear  cell-  (PBMC)-derived  antigen
presenting  cell  (APC)  were  labeled  with  a  19F-perfluorocarbon  (PFC)  and/or  activated  with  gra-
nulocyte macrophage  colony-stimulating  factor  (GM-CSF).  Viability,  phenotype  and  cell  lineage
characterization  preceded  19F  cellular  MRI  of  PFC+ PBMC  under  both  pre-clinical  9.4  Tesla  (T)
and clinical  3T  conditions  in  a  mouse  model.
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Results.  —  A  high  proportion  of  PBMC  incorporated  PFC  without  affecting  viability,  phenotype  or
cell lineage  composition.  PFC+ PBMC  were  in  vivo  migration-competent  to  draining  and  downs-
tream lymph  nodes.  GM-CSF  addition  to  culture  increased  PBMC  migration  to,  and  persistence
within, secondary  lymphoid  organs.
Conclusion.  —  19F  cellular  MRI  is  a  non-invasive  imaging  technique  capable  of  detecting  and
quantifying  in  vivo  cell  migration  in  conjunction  with  an  established  APC-based  immunotherapy
model. 19F  cellular  MRI  can  function  as  a  surrogate  marker  for  assessing  and  improving  upon
the therapeutic  benefit  that  this  immunotherapy  provides.
© 2020  L’Auteur(s).  Publié  par  Elsevier  Masson  SAS  au  nom  de  Société  française  de  radiologie.
Cet article  est  publié  en  Open  Access  sous  licence  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Introduction
The  ex  vivo  generation  of  antigen  presenting  cell-  (APC)-
based  cancer  immunotherapies  is  a  leading  strategy  to
avoid  and  combat  tumor-induced  immune  suppression  that
prevents  effective  anti-tumor  immune  responses  from
being  launched  [1—3].  Originally,  dendritic  cells  (DC)  were
employed  as  professional  APC  because  they  induce  potent
de  novo  tumor-associated  antigen-(TAA)-specific  immune
responses  [4].  Due  to  their  in  vivo  scarcity,  DC  can  be
differentiated  ex  vivo  from  monocytes  co-cultured  with
differentiation-inducing  growth  factors  such  as  granulo-
cyte  macrophage  colony-stimulating  factor  (GM-CSF)  [3,5].
Lengthy  ex  vivo  culture  is  often  required  to  produce
monocyte-derived  DC  (moDC)-based  immunotherapies  but
can  also  promote  tolerogenic  TAA-specific  immune  responses
upon  autologous  adoptive  transfer  [6,7].
To  reduce  extensive  ex  vivo  culture,  peripheral  blood
mononuclear  cells  (PBMC)  have  served  as  precursors  for
APC-based  immunotherapies.  An  example  is  Sipuleucel-T
(Provenge®),  which  is  a  cell-based  vaccine  for  the  treat-
ment  of  metastatic  castration-resistant  prostate  cancer
(mCRPC)  manufactured  by  culturing  PBMC  ex  vivo  with  GM-
CSF  linked  to  the  TAA,  prostatic  acid  phosphatase  (PAP)
[8].  GM-CSF  is  central  to  immunotherapeutic  effective-
ness  as  it  up-regulates  markers  of  activation,  migration,
co-stimulation  and  antigen  presentation  on  APC  [4,9,10].
Specifically,  CD54  present  on  activated  APC  stabilizes  the
immunological  synapse  between  APC  and  antigen-specific
CD4+/CD8+ T  cells  in  secondary  lymphoid  organs  to  induce
an  effective  TAA-specific  immune  response  [9,11].  Despite
GM-CSF  activation,  a  phase  III  clinical  trial  (NCT00065442)
reported  that  Provenge® only  prolonged  overall  survival  of
mCRPC  patients  by  4.1  months  [12].  This  is  similar  to  the
survival  benefit  reported  for  other  mCRPC  treatment  regi-
mens  [13]  yet  clearly  highlights  the  urgent  need  to  improve
mCRPC  immunotherapeutics.
With  APC-based  immunotherapies,  migration  to  secon-
dary  lymphoid  organs  is  not  only  essential  but  is  predictive
of  the  magnitude  of  the  ensuing  immune  response  as  well
[14—16].  Cellular  MRI  that  detects  both  fluorine-19  (19F)
and  anatomical/hydrogen-1  (1H)  signal  is  capable  of  quan-
titatively  tracking  human  and  mouse  19F-perfluorocarbon
(PFC)-labeled  cells  in  vivo  with  high  specificity  [17—20].
We  have  also  reported  the  in  vivo  detection  of  PFC+,  but
otherwise  unmanipulated,  human  PBMC  migration  to  drai-
ning  lymph  nodes  (LN)  by  both  9.4  Tesla  (T)  pre-clinical  and
3T  clinical  MRI  scanners  [21].
The  pre-clinical  characterization  of  therapeutic  APC  for-
mulations,  including  the  effect  of  cytokine  addition  to
ex  vivo  cultures  and  suitability  of  PFC  as  a  cell  tracking
agent,  are  critical  when  considering  clinical  implementa-
tion.  Due  to  the  heterogenous  composition  of  PBMC,  the
unique  immunotherapeutic  role  of  each  cell  lineage  must
also  be  preserved  [22]. We  expand  on  our  previous  studies
to  describe  in  vivo  PFC+ PBMC  migration  and  persistence  on
a  cell  lineage  basis  in  an  effort  to  identify  the  role  of  GM-
CSF-induced  activation  on  in  vivo  PBMC  fate  and  its  possible
association  with  immunotherapeutic  potency.
The  purpose  of  this  study  was  to  test  19F  cellular  MRI
as  a non-invasive  imaging  modality  to  track  therapeutic




Immunocompromised  male  NU/NU  mice  (Crl:NU-Foxn1NU)
were  purchased  from  Charles  River  Laboratories  (Saint  Cons-
tant,  CAN).  All  applicable  institutional  and/or  national
guidelines  for  the  care  and  use  of  animals  were  followed.
Participants
The  University  of  Western  Ontario  Health  Sciences  Research
Ethics  Board  (REB  Protocol  #104593)  pre-approved  this  pro-
tocol.  Each  participant  aged  18  years  or  older  provided
a  signed  letter  of  informed  consent  prior  to  periphe-
ral  blood  procurement  and  were  self-reported  free  of
human  immunodeficiency  virus,  hepatitis  B  and  C  virus  and
other  transmissible  diseases.  Commercially  available  PBMC
products  were  also  obtained  from  Stemcell  Technologies
(Seattle,  USA).  The  complete  reagent  list  is  organized  in
Supplemental  Table  1.
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PBMC isolation and PFC labeling
The  compatibility  of  GM-CSF  addition  to  culture  was  tested
with  a  previously  optimized  protocol  for  generating  PFC+
PBMC  [21].  Briefly,  peripheral  blood  or  leukapheresis  pro-
duct  was  diluted  with  Hank’s  balanced  salt  solution  and
underwent  density  gradient  centrifugation  (LymphoprepTM)
to  isolate  PBMC.  PBMC  were  resuspended  in  AIM  V®
Medium  CTSTM media  (5  ×  106 cells/mL)  and  labeled  with
PFC  (5.0  mg/mL)  or  remained  unlabeled  (UL)  for  the  first
24  hours  of  culture  at  37 ◦C,  5%  CO2,  and  co-cultured  ±  GM-
CSF  (20  ng/mL)  for  the  final  24  hours  of  a  total  48  hour
culture.
Alternatively,  PBMC  underwent  negative  magnetic  selec-
tion  using  manufacturer’s  instructions  to  enrich  for  T
cells,  B  cells  and  monocytes.  Enriched  cell  cultures  were
resuspended  in  AIM  V® Medium  CTSTM media  (±  PFC)  for
24  hours  followed  by  GM-CSF  addition  for  24  hours  further  in
NunclonTM SpheraTM low  attachment  plates  (Thermo  Fisher
Scientific).
Select  PBMC  samples  were  cryopreserved  for  long-term
storage.  Cryopreserved  PBMC  were  cultured  as  outlined
above  to  generate  GM-CSF-treated  PFC+ or  UL  PBMC,  with
the  only  modification  being  overnight  (∼18  hours)  rather
than  48-hour  culture.
PBMC viability
PBMC  viability  was  measured  using  Trypan  blue  exclusion.  To
more  stringently  determine  the  effect  of  GM-CSF  and  PFC  on
the  viability  of  both  bulk  PBMC  and  enriched  cell  lineages,
LIVE/DEADTM fixable  aqua  dead  cell  stain  was  used  as  descri-
bed  [21]  and  data  was  acquired  with  a  LSRII  analytical  flow
cytometer  (BD  Biosciences).
Flow cytometry
The  fluorescent  antibodies  listed  in  Supplemental  Table  1
were  used  for  phenotyping  following  an  aforementioned
protocol  [21].  For  experiments  pertaining  to  homogeneous
cell  lineage  culturing  (±  PFC),  T  cells  were  labeled  with
CellTraceTM Far  Red  (Far  Red),  B  cells  with  CellTraceTM Violet
(CTV)  and  monocytes  with  CellTraceTM Carboxyfluorescein
succinimidyl  ester  (CFSE)  membrane-intercalating  dyes  (all
1  M)  following  a  previously  detailed  protocol  [21]. Cell
lineage  enrichment  and  fluorescent  label  incorporation  was
verified  by  comparison  to  a  cell  aliquot  removed  before
in  vitro  processing.  All  data  was  acquired  using  a  BD  Bios-
ciences  LSRII  analytical  flow  cytometer.
Adoptive transfer of PBMC
The  in  vivo  migration  of  GM-CSF-treated  PFC+ PBMC  com-
pared  to  untreated  PFC+ PBMC  was  assessed  using  19F
MRI.  Three  hours  prior  to  PFC+ PBMC  administration,  mouse
interleukin-1  (IL-1, 300  ng)  was  injected  into  the  left
popliteal  LN  (pLN)  area  of  (n  =  4)  mice  per  donor  PBMC  to
improve  in  vivo  migration  [15,23].  Two  mice  received  hind
footpad  injections  of  3  ×  106 GM-CSF-treated  PFC+ PBMC
while  two  different  mice  received  3  ×  106 PFC+ PBMC  injec-
tions  per  PBMC  product  (n  =  4).  Injections  were  formulated
in  40  L  phosphate-buffered  saline.
Table  1  Clinical  3T  1H/19F  MR  imaging  parameters.
Parameters  1H  19F
TR  (ms)  12.8  5.8
TE  (ms)  6.4  2.9
BW  (kHz)  31.25  10
FA  (◦) 20  72
PC  6  1
NEX  1  200
FOV  (mm2) 60  ×  30  60  ×  30
Slice  thickness  (mm) 0.2  1
Matrix  size  (pixel) 300  ×  150 60  ×  30
Acquisition  time  (min) 25  35
TR: repetition time; TE: echo time; BW: bandwidth; FA: flip
angle; PC: phase cycles; NEX: number of excitations; FOV: field
of view.
Fluorescent  mono-lineage  cells  were  recombined  at
donor-specific  physiologic  proportions  (n  =  3)  to  formulate
3  ×  106 PFC+ and  3  ×  106 UL  PBMC  injections  into  the  right
and  left  hind  footpads,  respectively,  of  (n  =  4—5)  mice.  Sepa-
rately,  3  ×  106 PFC+ PBMC  and  control  UL  PBMC  from  (n  =  3)
donors  were  injected  into  one  hind  and  contralateral  hind
footpad,  respectively,  of  (n  =  3)  mice/donor.
In  a final  adoptive  transfer  experiment,  3  ×  106 and
6  ×  106 PFC+ GM-CSF-treated  PBMC  (n  =  3  cryopreserved
PBMC)  were  injected  into  the  right  hind  and  left  hind  foot-
pads,  respectively,  of  (n  =  2—3)  mice/donor.  All  mice  were
housed  for  two  days  after  injection  to  permit  in  vivo  PBMC
migration.
MRI and quantification of PFC+ PBMC migration
Imaging  was  performed  two  days  after  adoptive  transfer
on  a  9.4T  small  animal  MRI  scanner  (Varian)  using  identi-
cal  1H/19F  imaging  parameters  outlined  by  our  group  [21].
Mice  that  received  cryopreserved  PFC+ PBMC  underwent
1H/19F  MRI  at  both  24  and  48  hours  post  injection  on  a
3T  clinical  MRI  scanner  (Discovery® MR750,  General  Elec-
tric  Healthcare)  that  employed  a  dual-tuned  radiofrequency
surface  coil  (Clinical  MR  Solutions)  and  a  3D-balanced  steady
state  free  precession  sequence.  MR  acquisition  parameters
are  presented  in  Table  1  and  overlaid  1H/19F  composite
images  (Osirix,  Pixmeo  SARL)  provide  anatomical  reference.
Voxel  TrackerTM software  (Celsense,  Inc.)  quantified  in  vivo
19F  signal  relative  to  reference  tube  signals  containing
a  known  amount  of  19F  spins  (3.33  ×  1016 19F  spins/L)
[24,25].  The  mean  signal-to-noise  (SNR)  ratio  of  LNs  with
detectable  19F  signal  was  7.37  (range:  5.36—10.12)  at
3T.
Post-MRI verification of in vivo 19F signal
Following  MRI  completion,  pLNs  from  mice  that  received
triple-fluorescent  PBMC  (±  PFC)  were  processed  for  digital
fluorescence  imaging  as  previously  described  [19].  Alterna-
tively,  pLNs  from  mice  that  received  3  ×  106 non-fluorescent
PBMC  (±  PFC)  injections  were  processed  into  single  cell
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suspensions  and  surface  stained  for  human  CD45,  CD3,
CD20  and  CD14  as  stated  above.  Inguinal  LN  (iLN)  single  cell
suspensions  served  as  negative  controls.
Statistical analysis
Quantitative  variables  were  expressed  as  means  ±  SD  and
ranges.  A  paired  t-test  or  ANOVA  including  multiple  com-
parisons  with  Bonferroni  post-hoc  test  (Graph  Pad  Prism  8)
were  used  and  was  defined  when  statistics  were  reported.
Significance  was  set  at  P  ≤  0.05.
Results
GM-CSF promotes APC activation phenotype
without affecting viability or PFC loading
GM-CSF  (20  ng/mL)  addition  to  cell  cultures  did  not  affect
PFC+ PBMC  viability  (85.7  ±  4.6  [SD]  %;  range:  79.3—90.4%)
when  compared  to  the  PBMC  viability  cultured  without
GM-CSF  (88.7  ±  3.7  [SD]  %;  range:  85.4—93.8%)  (P  =  0.42)
(Fig.  1A).  Similarly,  GM-CSF  did  not  significantly  alter
intraparticipant  PFC  uptake  as  ascertained  using  NMR  spec-
troscopy  (2.27  ±  1.87  [SD]  ×  1011 19F  spins/cell  [range:
0.253—3.95  ×  1011 19F  spins/cell])  versus  (2.17  ±  1.60
[SD]  ×  1011 19F  spins/cell  [range:  0.633—3.83  ×  1011 19F
spins/cell])  in  the  presence  and  absence  of  GM-CSF,  res-
pectively  (P  =  0.75)  (Fig.  1B).  Additional  studies  revealed
that  both  GM-CSF  and  PFC  did  not  significantly  alter  PBMC
viability  on  a  cell  lineage  basis  (Supplemental  Fig.  1A).
It  was  also  determined  that  PFC  labeling  did  not  ove-
rall  impact  the  GM-CSF-induced  activated  PBMC  phenotype
(Supplemental  Fig.  1B—E)  and  thus,  GM-CSF-induced  PBMC
activation  may  present  with  enhanced  in  vivo  migration  of
PFC+ PBMC.
GM-CSF promotes in vivo migration of PFC+
PBMC
Both  1H  and  19F  MR  imaging  was  conducted  two  days  after
3  ×  106 PFC+ PBMC  (±  GM-CSF)  injections  into  both  hind
footpads  (n  =  4  donor  PBMC,  n  =  2  mice/donor/condition).
In  total,  GM-CSF-treated  PFC+ PBMC  were  detected  in  6  of
8  right  and  5  of  8  left  pLNs  (Figs.  2A/B  and  3A—C),  with
the  left  pLNs  having  received  IL-1 pre-treatment  and  right
pLNs  remaining  untreated.  In  vivo  PFC+ PBMC  migration  is
represented  by  anatomical/19F  MR  composite  images  pseu-
docoloured  using  a  ‘‘hot-iron’’  color  scale  (Figs.  2 and  3).
Untreated  PFC+ PBMC  produced  detectable  19F  signal  in  1
of  8  right  pLNs  and  7  of  8  left  pLNs  (Figs.  2C/D  and  3D—F).
For  pLNs  with  detectable  19F  signal,  the  signal  was  quan-
tified  as  the  number  of  PFC+ cells.  GM-CSF  appeared  to
activate  PFC+ PBMC  to  enhance  in  vivo  migration  above
the  19F  MRI  signal  threshold  and  thus,  permitted  consistent
detection  and  quantification  of  migrated  cells.  This  was
in  contrast  to  the  results  observed  for  untreated  PFC+
PBMC,  where  pre-treatment  of  the  pLN  region  with  IL-1
was  required  to  increase  the  migration  of  PFC+ PBMC  in
the  absence  of  GM-CSF  above  the  19F  MR  detection  thre-
shold.
Characterization of pLN migration-competent
PFC+ PBMC
Successful  in  vivo  19F  MRI  detection  and  quantification  of
PFC+ PBMC  (Figs.  2  and  3)  raised  questions  pertaining  to
the  cell  lineage  composition  of  pLN-migrated  PFC+ PBMC
and  how  this  composition  compares  to  pLN-migrated  UL
PBMC.  To  address  these  questions,  the  donor-specific  cell
lineage  composition  of  bulk  PBMC  was  determined,  follo-
wed  by  negative  enrichment  to  isolate  CD3+ T  cells  (Fig.  4
A),  CD19+CD20+ B  cells  (Fig.  4B)  and  CD14+/CD16+ mono-
cytes  (Fig.  4C)  to  >  95%  purity.  Each  lineage  was  ex  vivo
cultured  with  GM-CSF  and  labeled  with  PFC  or  remained
UL.  Two  days  later,  each  lineage  (±  PFC)  was  further  labe-
led  with  a  unique  membrane-intercalating  fluorophore  for
in  vivo  lineage  differentiation  (Fig.  4D—F).  UL  and  PFC+
lineages  were  similarly  labeled  and  to  >  99%  compared  to
non-fluorescent  lineage-matched  cells  (Fig.  4D—F).  No  signi-
ficant  viability  differences  between  pre-injection  UL  and
PFC+ lineages  were  noted  for  all  lineages  (data  not  shown).
Fluorescent  cell  lineages  were  then  recombined  to
closely  resemble  donor-specific  lineage  composition  and
formulated  into  3  ×  106 UL  or  PFC+ triple-fluorescent  left
and  right  hind  footpad  injections,  respectively.  The  mean
cell  lineage  composition  was  52.4  ±  22.2  [SD]  %  T  cells,
16.4  ±  18.1  [SD]  %  B  cells  and  31.2  ±  7.8  [SD]  %  monocytes
for  all  PBMC  products  (n  =  3  donors).  Two  days  after  adoptive
transfer,  all  cell  lineages  were  present  in  the  central  regions
of  pLN  cryosections  for  both  UL  (Fig.  4G)  and  PFC+ (Fig.  4H)
triple-fluorescent  injection  formulations.
Ideally,  PFC  should  label  all  cells  without  selectively
affecting  specific  lineages  or  sub-populations.  Therefore,
we  sought  to  quantify  and  compare  LN-migrated  PFC+ and
UL  PBMC  in  a  separate  experiment.  GM-CSF-activated  PBMC
were  cultured  as  described  above  to  generate  UL  PBMC
and  PFC+ PBMC  for  injection  into  the  left  and  right  hind
footpad,  respectively.  Pre-injection  lineage  analysis  revea-
led  no  significant  difference  in  the  percentage  of  CD3+
T  cells,  CD20+ B  cells  and  CD14+ monocytes  between  UL
and  PFC+ conditions  (Supplemental  Fig.  2A—C).  Two  days
later,  single  cell  suspensions  of  excised  pLNs  were  subject
to  flow  cytometric  analysis  to  identify  human  CD45+ cells
(Supplemental  Fig.  2D).  UL  and  PFC+ injection  conditions
did  not  significantly  differ  with  respect  to  the  mean  per-
centage  of  pLN-migrated  human  CD45+ cells  (UL:  0.85  ±  0.48
[SD]  %  vs.  PFC+: 0.94  ±  0.95  [SD]  %;  P  =  0.75)  (Fig.  4I),  as  well
as  the  mean  percentage  of  pLN-migrated  CD3+ T  cells  (UL:
72.2  ±  18.7  [SD]  %  vs.  PFC+: 79.0  ±  16.2%;  P  =  0.27)  (Fig.  4J),
CD20+ B  cells  (UL:  11.9  ±  9.1  [SD]  %  vs.  PFC+:  11.7  ±  10.4  [SD]
%;  P  =  0.96)  (Fig.  4K)  and  CD14+ monocytes  (UL:  6.5  ±  5.7  [SD]
%  vs.  PFC+: 4.4  ±  5.3  [SD]  %;  P  = 0.43)  (Fig.  4L).
Detection of GM-CSF-treated PFC+ PBMC
in vivo migration with a 3T clinical MRI set-up
To  apply  our  approach  from  a  pre-clinical  to  a  clinical
setting,  we  performed  in  vivo  human  PFC+ PBMC  migration
studies  under  clinical  3T  MRI  conditions.  Cryopreserved
PBMC  were  cultured  overnight  with  GM-CSF  (±  PFC)  to  gene-
rate  GM-CSF-activated  PFC+ and  UL  PBMC.  Mean  post-thaw
human  CD45+ PBMC  viability  was  96.3%  (range:  93.8—99.0%)
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Figure 1. Peripheral blood mononuclear cell (PBMC) viability and perfluorocarbon (PFC) incorporation was unaffected by granulocyte
macrophage colony-stimulating factor (GM-CSF). PBMC were labeled with PFC for a total of 48 hours (± GM-CSF addition for the final
24 hours). GM-CSF did not significantly affect PBMC viability (A, 85.7 ± 4.6 [SD] % vs. 88.7 ± 3.7 [SD] %) and average PFC loading (B, 2.27 ± 1.87
[SD] × 1011 vs. 2.17 ± 1.60[SD] × 1011 19F spins/cell). Data are shown as means ± SD for n = 3 independent experiments (paired t-test,
P > 0.05).
Figure 2. 19F MRI quantification of peripheral blood mononuclear cell (PBMC) in vivo migration. Overlaid 1H/19F MR composite images
identified right (R, blue arrows) and left (L, red arrows) popliteal lymph nodes (pLNs) from mice that received perfluorocarbon+ (PFC+)
granulocyte macrophage colony-stimulating factor (GM-CSF)-treated PBMC injections (A and B) or PFC+ PBMC injections (C and D). 19F
signal detected in pLNs is displayed in ‘‘hot-iron’’ colour scale and quantified as the number of PFC+ cells (A—D). All left pLN areas received
IL-1 pre-treatment (300 ng) three hours before PBMC injection. A reference tube is outlined with a hand-drawn white line and data are
presented for n = 4 mice injected with n = 1 donor PBMC.
(Fig.  5  A)  and  92.2%  and  89.5%  of  UL  and  PFC+ CD45+ PBMC,
respectively,  remained  viable  after  overnight  culture  (UL
range:  91.6—92.9%  and  PFC+ range:  87.5—92.4%)  (Fig.  5A).
PFC  labeling  did  not  alter  T  cell,  B  cell  or  monocyte  viability
(Fig.  5A)  or  percent  composition  (Fig.  5B)  compared  to
lineage-matched  UL  PBMC.  Nearly  100%  of  PBMC  incorpo-
rated  red  fluorescent  PFC  compared  to  UL  PBMC  (Fig.  5C),
with  PFC  incorporation  measured  at  1.15  ±  0.798  ×  1012
19F  spins/cell  (range:  0.47—2.03  ×  1012 19F  spins/cell)
(n  =  3  donors)  (Fig.  5D).  Clinical  3T  1H/19F  MR  imaging  was
performed  both  one  day  and  two  days  following  right  and
left  hind  footpad  injections  (n  =  2—3  mice/donor).  Day  1
(Fig.  5E)  and  day  2  (Fig.  5F)  1H/19F  MRI  detected  PFC+ cells
at  the  injection  site  (red  arrows),  pLNs  (orange  squares)  and
iLNs  (white  brackets).  A  representative  composite  1H/19F
three-dimensional  MRI  video  is  depicted  in  Supplemental
Movie  1. PFC+ cell  migration  to  pLNs  and  iLNs  (Fig.  5  was
quantified  on  day  1  and  day  2  (Fig.  5G)  and  ranged  from
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Figure 3. Granulocyte macrophage colony-stimulating factor (GM-CSF)-activation enhanced perfluorocarbon+ (PFC+) peripheral blood
mononuclear cell (PBMC) migration to mouse popliteal lymph nodes (pLNs). The adoptive transfer outlined in Fig. 2 was repeated with n = 3
donor PBMC. Composite 1H/19F MR images displayed right (R, blue arrows) and left (L, red arrows) pLNs for GM-CSF-treated PFC+ PBMC
injected mice (A—C) and similarly for PFC+ PBMC injected mice (D—F). All left pLN areas were pre-treated with IL-1 (300 ng) three hours
before PBMC injection. Hand-drawn white lines delineate a reference tube and quantifiable 19F signal in pLNs was shown as number of PFC+
cells. Collectively, data are shown for n = 4 PBMC donors (n = 4 mice/donor).
0.425—7.08  ×  105 (day  1)  and  0.24—3.41  ×  105 PFC+ cells
(day  2)  in  the  pLNs,  while  ranges  of  2.37—7.40  ×  105 and
0.278—4.61  ×  105 PFC+ cells  were  quantified  in  the  iLNs  on
day  1  and  day  2,  respectively.  Mice  receiving  the  higher
injection  dose  had  migration  ranging  from  0.115—9.06  ×  105
(day  1)  and  0.608—9.16  ×  105 PFC+ cells  (day  2)  in  the
pLNs  and  ranging  from  0.991—6.91  ×  105 (day  1)  and
0.888—9.89  ×  105 PFC+ cells  (day  2)  in  iLNs.  The  detection
of  human  CD45+ cells  in  single  cell  suspensions  of  excised
pLNs  and  iLNs  (Fig.  5H)  ensured  that  previously  cryopreser-
ved  GM-CSF-activated  PFC+ PBMC  were  producing  the  in  vivo
19F  signal  detected  using  a  3T  clinical  MR  configuration.
Discussion
This  study  was  designed  to  characterize  PFC+ PBMC  on
a  cell  lineage  basis  and  determine  the  compatibility  of
19F  MRI  for  in  vivo  cell  tracking  in  conjunction  with  an
established  APC-based  immunotherapy  model  [8].  Although
previous  work  has  described  PFC  labeling  of  all  PBMC
cell  subsets  [21],  characterization  of  secondary  lymphoid
organ-migrated  PFC+ PBMC  subsets  has  not  been  reported.
This  critical  gap  in  knowledge  reduces  the  accuracy  of
using  in  vivo  imaging  as  a  biomarker  of  immunotherapeutic
effectiveness  as  each  cell  lineage  within  PBMC  serves  a
unique  and  necessary  immunological  function.
Prior PFC labeling does not interfere with
GM-CSF-mediated APC activation
We  have  previously  optimized  conditions  for  labeling  nearly
100%  of  human  PBMC  with  PFC  [21]  to  improve  19F  MRI
detection  sensitivity.  This  is  an  important  concept  to  consi-
der  given  the  added  complexity  of  labeling  heterogenous
cell  populations  such  as  PBMC,  which  is  well  represented
by  a  previous  study  that  reported  fluorescent  PFC  uptake  in
3.70  ±  0.21  (SD)  %  of  CD3+ cells  [26]  contained  within  bulk
splenocytes,  while  90%  of  human  CD3+ T  cells  incorporated
PFC  in  homogeneous  culture  [17].  Cell  populations  with  low
cytoplasmic  volume  such  as  B  and  T  lymphocytes  that  have
proven  difficult  to  label  with  contrast  agents  in  the  past
[27,28]  efficiently  incorporated  PFC  under  our  optimized
culture  conditions.
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Figure 4. All three main peripheral blood mononuclear cell (PBMC) cell lineages are in vivo popliteal lymph node (pLN) migration-
competent. Enriched CD3+ T cell (A), CD19+CD20+ B cell (B) and CD14+/CD16+ monocyte (C) lineages were cultured for 48 hours
(± perfluorocarbon [PFC]), with granulocyte macrophage colony-stimulating factor (GM-CSF) added for the final 24 hours. Nearly 100%
of unlabeled (UL) (closed histograms) and PFC+ (open histograms) T cells fluoresced Far Red+ (D), B cells CTV+ (E) and monocytes CFSE+
(F) compared to non-fluorescent UL and PFC+ controls (D—F, closed and open grey histograms, respectively). Recombined triple-fluorescent
PBMC were formulated into UL and PFC+ hind footpad injections and two days later, excised pLNs contained all 3 cell lineages for both
UL and PFC+ PBMC, respectively (G and H, scale bars = 50 m and white lines outlined pLNs at 100 × magnification). Separately, pLN were
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We  next  assessed  PFC  labeling  of  PBMC  in  conjunction
with  GM-CSF  addition  to  culture.  PBMC  were  labeled  with
PFC  prior  to  GM-CSF  addition  to  take  advantage  of  the
impressive  PFC  uptake  by  APC  within  PBMC  when  in  an
unactivated  state.  Efficient  PFC  uptake  occurred  before  GM-
CSF-induced  APC  activation.  APC  activation  demonstrated
here  may  coincide  with  decreased  antigen  uptake  and  pre-
sumably,  decreased  PFC  uptake  as  has  been  reported  for
DC  [10,21,29].  PBMC  viability  remained  consistently  high
(>  85%)  throughout  culture,  which  was  expected  considering
PFC  is  comprised  of  an  inert  emulsion  stabilized  by  surfac-
tant  and  is  retained  within  the  viable  cell  populations  of
interest  [18,30].  Interparticipant  differences  in  PFC  incor-
poration  were  attributed  to  the  wide  range  of  cell  lineage
proportions  within  PBMC  that  range  from  18.7—71.4%  for  T
cells,  3.36—27.7%  for  B  cells  and  7.14—45.3%  for  monocytes
[22]  and  although  unavoidable,  this  must  be  considered  with
respect  to  19F  MRI  sensitivity.
Each  cell  lineage  serves  a  specific  and  necessary  immuno-
logical  purpose  and  thus,  it  was  imperative  to  demonstrate
that  PFC  did  not  disproportionately  affect  the  viability,
phenotype  and  function  of  specific  cell  lineages.  PBMC  phe-
notype  was  assessed  both  by  frequency  and  intensity  of
expression  (MFI)  for  activation,  co-stimulation  and  migra-
tion  markers  required  for  APC  to  function  as  adjuvants  in
an  immunotherapeutic  setting.  For  all  culture  conditions,
both  B  cells  and  myeloid  cells  expressed  CD40,  CD86  and
CD54.  Nearly  all  UL  and  PFC+ B  cells  were  CD40+,  which  is
critical  for  induction  of  TH1-mediated  and  TH2-/humoral-
mediated  immune  response  through  interaction  with  CD154
on  CD4+ TH cells  [9,29].  In  mCRPC  patients  that  recei-
ved  Sipuleucel-T  (Provenge®),  from  two  weeks  up  until
6  months,  IgG  responses  to  PAP  and  other  non-targeted  TAA
arising  from  antigen  spread  (prostate-specific  antigen  and
LGALS3/Galectin  3)  were  associated  with  prolonged  overall
survival  [31].  Furthermore,  CD54+ APC  that  co-express  CD40,
CD86  and  human  leukocyte  antigen  (HLA)-A,  B,  C  and  HLA-DR
can  present  TAA  alongside  appropriate  co-stimulatory  signal-
ling  necessary  to  induce  both  TAA-specific  CD8+ and  CD4+ T
cells  [32—34].  GM-CSF  moderately  induced  APC  to  express
an  activated  phenotype  that  included  significant  upregula-
tion  of  CD86  on  B  cells  and  significant  upregulation  of  CD86
and  CD54  on  myeloid  cells,  suggesting  that  GM-CSF  is  biolo-
gically  active  in  our  experimental  system.  We  also  believe
that  the  CD54+ myeloid  cells  reported  here  closely  mimic
the  large  CD54+ APC  within  Sipuleucel-T  (Provenge®) cell
products  [12].
19F MRI detection and quantification of PFC+
PBMC in vivo migration at 9.4T
We  next  sought  to  determine  if  19F  MRI  was  a  sui-
table  imaging  modality  to  detect  differences  in  PFC+
PBMC  in  vivo  migration  associated  with  GM-CSF  inclu-
sion  in  culture.  Pre-treatment  of  the  draining  pLN  with
IL-1  before  adoptive  cell  transfer  was  also  included
to  improve  in  vivo  PFC+ PBMC  migration  as  a  means
of  enhancing  immunotherapeutic  effectiveness  [15,23,35].
GM-CSF-activation  of  PFC+ PBMC  and  IL-1 pre-treatment  of
recipient  mice  did  not  function  synergistically  to  improve
PFC+ PBMC  migration  to  the  pLN.  However,  IL-1 pre-
treatment  appeared  to  improve  migration  above  the  19F
MRI  detection  threshold  for  PFC+ PBMC  not  activated  with
GM-CSF.
GM-CSF-activated  PFC+ PBMC  exhibited  an  improved
capacity  to  reach  the  draining  pLN  that  permitted  consistent
detection  and  quantification  using  19F  MRI.  GM-CSF  did  not
affect  expression  of  the  migration  marker  CCR7  as  asses-
sed  here;  however,  GM-CSF  has  been  shown  to  modulate
the  expression  other  chemokine  receptors  such  as  CCR5
and  CXCR4  that  mediate  cell  migration  to,  and  retention
within,  secondary  lymphoid  organs  [36,37].  Alternatively,
GM-CSF  activation  of  PFC+ PBMC,  through  interaction  with  its
cognate  receptor  CD116,  induces  CD54  upregulation.  CD54,
alternatively  known  as  intracellular  adhesion  molecule  1
(ICAM-1),  stabilizes  the  immunological  synapse  between
APC  and  T  cell  via  interaction  with  lymphocyte  function-
associated  antigen  1  [11,38,39]. We  have  previously  shown
in  vitro  that  both  PFC+ and  control  UL  APC  are  equally
capable  of  inducing  allogeneic  CD4+ and  CD8+ T  cell  pro-
liferation  in  a  human  mixed  lymphocyte  reaction  and  that
PFC+ and  control  UL  mouse  bone  marrow-derived  DC  equi-
valently  stimulate  an  antigen-specific  CD8+ T  cell  response
in  immunocompetent  C57BL/6  mice  [19,21].  Therefore,
we  predict  that  GM-CSF  activation  of  PBMC  promotes
APC  retention  in  the  LN,  thereby  fostering  immunologi-
cally  successful  interactions  with  T  cells,  and  resulting  in
an  improved  immunogenicity  of  the  subsequent  antigen-
specific  immune  response  [40].  Moreover,  activated  APC
within  PBMC  can  contribute  to  a  positive  feedback  loop
via  IL-12  and  IFN  release.  These  pro-inflammatory  cyto-
kines  activate  T  and  natural  killer  cells  to  release  TNF and
additional  IFN  that,  in  turn,  can  then  activate  APC  in  a
paracrine  manner  [34,41].  With  this  outlined  mechanism,
GM-CSF-induced  APC  activation  and  positive  feedback  pro-
inflammatory  cytokine  secretion  could  present  as  increased
PFC+ PBMC  in  the  pLN  as  quantified  by  19F  MRI  in  this
study.
Characterization of pLN-migrated PFC+ cells
The  question  arose  following  successful  PFC+ PBMC  detec-
tion  in  pLNs  with  19F  MRI  as  to  which  cell  lineages
were  contributing  to  the  measured  19F  signal.  Until  this
point,  it  was  assumed  that  the  relative  cell  lineage  pro-
portions  in  pre-injection  PFC+ PBMC  were  similar  to  the
LN-migrated  cell  lineage  proportions.  Secondly,  from  an
digested 48 hours following hind footpad injection of GM-CSF-treated non-fluorescent UL and PFC+ PBMC to identify pLN-migrated human
CD45+ using flow cytometry (I, white and black data points, respectively). No significant differences in quantified pLN-migrated human CD3+
T cells (J), human CD20+ B cells (K) and human CD14+ monocytes (L) were noted between UL and PFC+ injection conditions. Data are shown
for n = 3 donor PBMC (n = 4—5 mice/donor) (A—H). For panels I—L, data was expressed as means ± SD for n = 3 donor PBMC (n = 3 mice/donor)
(I—L, P > 0.05).
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Figure 5. Clinical 3T MRI detection of cryopreserved perfluorocarbon+ (PFC+) peripheral blood mononuclear cell (PBMC) migration to
draining mouse lymph nodes (LNs). Post-thaw CD45+ PBMC viability was 96.3 ± 2.6% (A, day 0) and remained high after culture with gra-
nulocyte macrophage colony-stimulating factor (GM-CSF) for both unlabeled (UL) and PFC+ total CD45+ PBMC, as well as for T cell, B cell
and monocyte lineages (A, day 1, white and black bars, respectively). PFC incorporation did not alter cell lineage composition compared
to UL PBMC (B, day 1, white and black bars, respectively). Nearly 100% of PBMC incorporated red fluorescent PFC (C, red histogram, UL
PBMC gray histogram) and the mean PFC loading was 1.15 ± 0.798 × 1012 19F spins/cell for n = 3 donor PBMC (D). Mice (n = 2—3/donor) that
received 3 × 106 and 6 × 106 PFC+ PBMC right (R) and (L) hind footpad injections, respectively, had 19F signal detected at both 24 hours
(E) and 48 hours (F) at the footpad (red arrows), popliteal LNs (pLNs, orange boxes) and inguinal LNs (iLN, white brackets). Quantified 19F
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immunological  perspective,  defining  and  quantifying  which
cell  lineages  reach  the  LN  is  important  due  to  the  defi-
ned  functions  each  lineage  serves  in  secondary  lymphoid
organs.
By  labeling  enriched  GM-CSF-treated  CD3+ T  cells,
CD19+CD20+ B  cells  and  CD14+/CD16+ monocytes  with  unique
fluorophores  we  were  not  only  able  to  assess  in  vivo  migra-
tion  of  PBMC  on  a  per  lineage  basis  but  also  compare
this  migration  between  UL  and  PFC+ conditions.  A  slight
decrease  in  CFSE  fluorescence  was  noted  in  PFC+ monocytes
compared  to  UL  monocytes  and  is  most  likely  a  result  of
monocytes  incorporating  the  largest  amount  of  PFC.  Even  so,
the  fluorescence  from  CFSE-labeled  PFC+ monocytes  is  mul-
tiple  log  folds  higher  than  for  CFSENeg monocytes,  rendering
them  easily  distinguishable  from  non-fluorescent  surroun-
ding  cells.  PFC  labeling  does  not  interfere  with  in  vivo
migration  as  all  three  main  lineages  from  both  UL  and  PFC+
PBMC  were  detected  in  the  pLN,  with  the  majority  of  cells
penetrating  into  central  paracortical  and  follicular  regions
of  this  organ.  The  observed  penetrance  of  CFSE+ monocytes
into  central  LN  regions  suggests  that  such  monocytes  dif-
ferentiated  into  moDC  due  to  GM-CSF  addition  to  culture,
further  confirming  GM-CSF  bioactivity  in  our  cultures  [42].
Considering  that  the  monocyte  to  moDC  transition  and  sub-
sequent  maturation  is  dynamic  and  continues  throughout
in  vivo  migration  to  the  LN  the  slight  differences  in  APC
activation  state  between  PFC+ and  UL  conditions  prior  to
injection  may  be  restored  or  modified  upon  reaching  the
pLN.  Further  phenotyping  for  HLA-DR  and  CD11c  upregula-
tion,  cytokine  secretion  profiles,  as  well  as  quantification  of
the  ensuing  TAA-specific  immune  response  would  be  requi-
red  to  fully  answer  this  hypothesis.  The  implications  of
monocyte  to  DC  differentiation  are  promising  given  that  DC
are  professional  APC  capable  of  launching  long-term  potent
de  novo  immune  responses  through  interaction  and  activa-
tion  of  naïve  CD4+ and  CD8+ T  cells  [32,35]  in  paracortical
LN  regions.
The  previous  experiment  required  extensive  ex  vivo
manipulation  and  lineage  enrichment,  which  have  the
potential  to  alter  cell  activation  status  [43].  To  accura-
tely  quantify  in  vivo  migration,  we  conducted  a  separate
experiment  void  of  numerous  ex  vivo  manipulation  steps.
Flow  cytometric  analysis  of  LN  cell  suspensions  revea-
led  that  PFC  labeling  of  PBMC  did  not  interfere  with
the  number  of  pLN-migrated  human  CD45+ compared  to
UL  PBMC  and  that  PFC  labeling  did  not  disproportiona-
tely  affect  one  cell  lineage  over  another.  Additionally,  the
composition  of  pLN-migrated  human  CD45+ cells  closely
resembled  the  pre-injection  PBMC  composition.  Taken  toge-
ther,  this  data  confirms  our  previous  assumption  of  PFC+
PBMC  composition  remaining  constant  after  in  vivo  migra-
tion  holds  true  and  therefore,  quantification  of  in  vivo
PBMC  migration  using  19F  MRI  stands  as  an  accurate  and
non-invasive  biomarker  of  APC-based  immunotherapeutic
effectiveness.
Cryopreserved PFC+ PBMC are lymph node
migration-competent and detectable using a
clinical 3T 19F MRI configuration
We  transitioned  from  pre-clinical  (9.4T)  to  our  current  cli-
nical  (3T)  MRI  set-up  that  included  a hardware  upgrade  for
dual  nuclei  (1H/19F)  detection  and  employed  a  highly  sensi-
tive  surface  coil  to  combat  the  lower  sensitivity  associated
with  19F  cellular  MRI.  SNR  was  improved  through  averaging
alongside  aforementioned  optimized  PFC  labeling  conditions
to  render  highly  specific  ‘‘hot-spot’’  detection  of  19F  MR
signal  possible  in  a  clinical  setting  [18,20,21,27,44].  Clinical
tracking  of  PFC+ DC  has  been  described  and  we  have  outli-
ned  a  Good  Manufacturing  Practice-compliant  protocol  that
yields  in  vivo  LN  migration-competent  PFC+ PBMC  detected
at  9.4T  [21,45].  We  then  shortened  our  ex  vivo  protocol  and
used  cryopreserved  PBMC  to  test  the  robustness  of  19F  MRI
therapeutic  cell  tracking  in  a clinical  setting.
With  a  shortened  protocol  for  PFC  labeling  and  GM-CSF
addition  to  culture,  nearly  100%  of  previously  cryopreser-
ved  PBMC  incorporated  PFC  similarly  to  fresh  PBMC.  Neither
cryopreservation  nor  PFC  labeling  reduced  PBMC  viability  in
our  hands,  which  is  immunologically  important  given  that
apoptotic  APC  can  lead  to  induction  of  tolerance  in  a  can-
cer  immunotherapy  model  [9].  Purposeful  migration  of  PFC+
PBMC  to  draining  pLN  and  downstream  iLNs  demonstrated
that  cryopreservation  does  not  alter  PBMC  in  vivo  migration.
Together  with  positive  cell  surface  staining  for  human  CD45+
cells  in  excised  LN  cell  suspensions  shown  by  our  group  [21],
we  are  confident  that  the  originally-injected  PFC+ human
PBMC  are  the  source  of  detected  in  vivo  19F  MR  signal.
This  also  indicates  that  the  majority  of  LN-migrated  human
CD45+ cells  remain  intact  and  viable,  and  thus,  false  posi-
tive  signal  due  to  apoptotic  human  PFC+ cell  engulfment  by
mouse  resident  phagocytes  is  not  confounding  our  obser-
ved  results.  Finally,  longitudinal  detection  of  PFC+ PBMC  in
pLNs  and  iLNs  both  one  day  and  two  days  after  adoptive
transfer  provides  further  evidence  supporting  our  proposed
mechanism  of  GM-CSF-induced  migration  to  and  retention
of  activated  APC  within  secondary  lymphoid  organs.
Conclusion
In  conclusion,  this  study  further  details  the  suitability  of
19F  MRI  as  a  non-invasive  imaging  modality  to  predict  APC-
based  vaccine  immunotherapy  effectiveness  that  is  robust
enough  to  handle  unavoidable  interpatient  differences  in
PBMC  composition  yet  sensitive  enough  to  detect  subtle
differences  in  in  vivo  PBMC  migration  as  a  result  of  APC  acti-
vation  using  an  established  method  [8].  What  started  as  a
drawback  —  labeling  a  heterogeneous  cell  population  with
PFC  —  resulted  in  the  successful  labeling  of  other  PBMC  cell
lineages  with  distinct  functions  that  play  key  roles  in  other
current  and  emerging  immunotherapies.
signal was summarized in (G). Human CD45+ PFC+ PBMC detected in pLN cell suspensions (H, red box) confirmed that originally-injected
PFC+ PBMC are the source of in vivo 19F signal.
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